A subsequent phase 2 clinical trial focusing on non-metastatic high-risk prostate cancer with biochemical recurrence revealed improved 2 year metastasis-free survival only in a specific subgroup with rapid PSA doubling time (NCT01341652) [155]. Here, KLK3 is linked to prostate cancer.